• / Free eNewsletters & Magazine
  • / My Account
Home>Authors>Damien Conover

Related Topics

  1. Jeremy Glaser
  2. Alex Morozov
  3. Friday Five
  4. Material Processing
  5. Media General A
  6. Coates International

Popular Topics

  1. Procter & Gamble
  2. Sears Holdings
  3. Dean Foods
  4. Emerging Markets
  5. Stock Market

Damien Conover

  1. All
  2. Videos
  3. Investing
  4. Research
  1. The Friday Five

    Five stats from the market and the stories behind them. This week: content kings, patent cliffs, and 30,000 head to Omaha.

  2. Significant Upside for Pharma Stock Prices, Dividends

    Pharmaceutical firms' adept handling of patent expirations has boosted investors' opinions of the sector, says Morningstar's Damien Conover .

  3. Is Pharma Still Defensive?

    Despite looming government health-care cuts, pharma stocks should hold up better-than-average in an economic slowdown, according to Morningstar's Damien Conover .

  4. Pharma Stocks Still a Bargain

    Despite the strong performance of health-care stocks in the second quarter, there are still plenty of good buying opportunities in the sector, according to Morningstar's Damien Conover .

  5. Better Days Ahead for Pharma Firms

    Valuations for pharmaceutical companies should rebound once investors look past today's patent expirations to tomorrow's new drugs, says Morningstar's Damien Conover .

  6. Has Health-Care Reform Eroded Pharma's Economic Moat?

    Pricing power may be diminished somewhat, but patent protections should continue to bolster big pharma's competitive advantage, says Morningstar's Damien Conover .

  7. Cost-Cutting Boosting Pharma Earnings

    Big pharmaceutical companies are getting lean in an attempt to boost profitability before they lose patent protection on several important drugs, says Morningstar's Damien Conover .

  8. Pfizer Shares Still Attractive

    A new CEO, a $5 billion share-repurchase program, and a handful of promising new drugs make Pfizer shares look cheap even after today's runup, according to Morningstar's Damien Conover .

  9. Will Reform Put a Target on Pharma's Back?

    Morningstar's Damien Conover says that current reform proposals are more like a slingshot than a rifle aimed at pharmaceutical companies--which are currently priced for a worst-case scenario.

  10. Upside Attraction to J&J

    Morningstar's Damien Conover discusses the prospects for J&J's stent and drug pipelines.

1234
Our Products
Tools
Resources
Services
Upcoming Events
Conferences
Webinars

©2012 Morningstar Advisor. All right reserved.